Is BPC-157 Legal in Kentucky? How to Access It Through Legitimate Channels

Where BPC-157 sits in federal compounding rules

BPC-157 is not an FDA-approved drug; FDA's July 2026 review found no approved product containing it in any country it searched [1]. On FDA's list of nominated bulk substances for state-licensed pharmacies and physicians (updated May 14, 2026), it appears in none of the three categories, so FDA's category 1 policy does not cover it [2].

BPC-157 sat on FDA's separate table of bulk substances that may present significant safety risks from September 2023 until April 22, 2026, when the nominating groups withdrew; it now appears in a 'nominated but withdrawn' table [5][4]. Removal was not a finding of safety, and FDA's page still carries its stated concerns about immunogenicity risk for certain routes of administration and peptide-related impurities [5].

FDA's own reviewers proposed that BPC-157 not be added to the pharmacy bulks list. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding it, against FDA staff's recommendation; that vote is advice only, and BPC-157 is not on the list [1][6].

The October 2026 HHS draft policy

On October 28, 2026 HHS filed notice of a draft enforcement-discretion policy covering six peptides, including BPC-157, scheduled for Federal Register publication on October 30, 2026 with public comment for two weeks after [3][4]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding a listed peptide while FDA's list is developed through rulemaking, if conditions are met [3][4].

The conditions for BPC-157 include BPC-157 acetate only, subcutaneous, intramuscular, oral or topical forms, a single active ingredient, bulk substance from an FDA-registered manufacturer with a valid certificate of analysis, and a patient-specific prescription [4].

The notice states it 'does not establish any rights for any person and is not binding on HHS or the public' [3][4]. Compounded drugs are not FDA-approved; FDA does not review their safety, effectiveness or quality before marketing [8].

What is known about safety

FDA's adverse-event search through December 4, 2025 found 3 reports, all for injectable BPC-157, and FDA said it cannot tell whether BPC-157 caused them [1]. In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short and small and gave limited safety information; headache and flatulence were the most frequent events after healthy-volunteer enemas [1]. FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1]. A 2026 systematic review found 3 studies covering 30 patients, all of poor quality, with certainty rated very low [9].